SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports that Nvidias board may remove Jensen Huang over alleged relationshipsincluding a reported connection to a suspected Chinese intelligence operativehave driven discussion of leadership and national-security risks. Traders are split between fearing disruption and further selling if Huang leaves and viewing the controversy as an overreaction that does not change Nvidias business prospects.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally centers on the FDAs Nov. 22 decision on deramiocel for Duchenne muscular dystrophy; managements confidence and comments about possible labeling have fueled optimism, alongside analyst upgrades. Traders remain divided over approval given prior FDA concerns, while claims of a leak or an impending short squeeze are speculative.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is drawing attention as traders rotate into rival chipmakers amid reports that Nvidias board is weighing Jensen Huangs future after misconduct allegations. Many see Nvidias leadership uncertainty as a near-term tailwind for AMD, while others argue the headlines do not change chip competitiveness and caution that a broader AI-sector pullback could weigh on AMD too.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos earnings report and guidance are the main focus, particularly whether AI infrastructure orders translate into delivered revenue and cash generation. Bullish traders see AI networking demand as a growth driver, while skeptics question whether orders are lumpy or vulnerable to hyperscaler capex cuts and flag inventory and margin pressure.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment includes To-Home businesses, which include Ele.me, local services and delivery platforms, and Taoxianda, and To-Destination segment businesses, which include Amap, the provider of mobile digital maps, navigation and real-time traffic information, and restaurant and local services guide platforms. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solutions. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibabas persistent weakness is drawing attention amid concerns that Nvidia chip-diversion and espionage allegations could create indirect scrutiny or export-control risks for its AI business; traders disagree over whether the reported links are credible. Some view the proposed Hong Kong IPO of chip unit T-Head as a positive, but others remain focused on China-related risks and the stocks weak price action.

GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

Reports and rumors about Nvidias board considering a leadership change involving Jensen Huang are driving volatility in NVDL, with traders debating the potential fallout. Many are buying the dip ahead of Nvidias earnings, while others warn that the ETFs 2x daily leverage can magnify further losses.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumbles Q3 results are driving attention, with record revenue, its AI infrastructure business becoming the main growth engine, and its first positive adjusted EBITDA quarter fueling the rally. Bulls are also touting short-squeeze potential, while skeptics point to ongoing cash needs, a softer next-quarter outlook, and uncertainty around financing and data-center expansion.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 167.55615276 USD and is down -7.61 over the last 24 hours. It is currently trading on 414 active market(s) with $110,681,799.54 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

QNT is drawing attention after a sharp pullback, with traders debating whether the weakness is a buying opportunity or a breakdown and watching technical support. Long-term bulls point to Quants anticipated role in tokenized banking and a planned Clearing House rollout, while skeptics question whether that adoption will create meaningful demand for the token.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is drawing attention ahead of its quarterly report, with traders focused on whether AI-driven fab investment and equipment orders can sustain growth; some see the chip-equipment rebound as encouraging, while others warn that capex could weaken and orders may be pushed out. The broader semiconductor rally is adding support to the discussion.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris strong Q3 growth, led by Recorlev, and raised revenue outlook are driving attention, with traders citing the results and analyst upgrades as support for the rally. Some are taking profits or questioning the valuation, while takeover talk remains speculation rather than a confirmed catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INOVIO to Participate in Upcoming Investor Conferences

INOVIO to Participate in Upcoming Investor Conferences INOVIO to Participate in Upcoming Investor ConferencesPR NewswirePLYMOUTH MEETING, Pa., Nov. 11, 2026 PLYMOUTH MEETING, Pa., Nov. 11, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA...

INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights

INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights INOVIO Reports Third Quarter 2026 Financial Results and Recent Business HighlightsPR NewswirePLYMOUTH MEETING, Pa., Nov. 10, 2026 VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted...

INOVIO Announces Pricing of Approximately $75 Million Public Offering

INOVIO Announces Pricing of Approximately $75 Million Public Offering INOVIO Announces Pricing of Approximately $75 Million Public OfferingPR NewswirePLYMOUTH MEETING, Pa., Nov. 5, 2026 PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology...

INOVIO Announces Proposed Public Offering of its Common Stock

INOVIO Announces Proposed Public Offering of its Common Stock INOVIO Announces Proposed Public Offering of its Common StockPR NewswirePLYMOUTH MEETING, Pa., Nov. 5, 2026 PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused...

INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026

INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026 INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026PR NewswirePLYMOUTH MEETING, Pa., Nov. 2, 2026 PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company...

INOVIO to Participate in Upcoming Scientific Conferences

INOVIO to Participate in Upcoming Scientific Conferences INOVIO to Participate in Upcoming Scientific ConferencesPR NewswirePLYMOUTH MEETING, Pa., Nov. 2, 2026 PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing...

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

PGEN's Q3 results hinge on Papzimeos sales momentum and pipeline updates as competitive threat grows from a newly approved RRP therapy.

Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket

Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.read more...

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings 

Equity

Stocktwits sentiment for PGEN hit a record 94/100 in ‘extremely bullish’ territory, with Wednesday’s earnings approaching.

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next 

Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.

$INO Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.50 up 42.53% YoY
• Reported revenue of $0.3M
• Inovio expects cash runway to extend into late fourth quarter 2027, without giving effect to further capital raising activities; the filing provides no quantified revenue, margin, or earnings guidance.

Stocktwits

Inovio Pharmaceuticals Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.50 up 42.53% YoY
• Reported revenue of $0.3M
• Inovio expects cash runway to extend into late fourth quarter 2027, without giving effect to further capital raising activities; the filing provides no quantified revenue, margin, or earnings guidance.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.50 up 42.53% YoY
• Reported revenue of $0.3M
• Inovio expects cash runway to extend into late fourth quarter 2027, without giving effect to further capital raising activities; the filing provides no quantified revenue, margin, or earnings guidance.

Inovio reported a $38M working capital deficit and substantial doubt beyond Q4 2027, faces confirmatory-study requirements for VOCERYQ, and competes with PAPZIMEOS while relying on third parties for sales.

Inovio received FDA accelerated approval for VOCERYQ, plans U.S. launch deployment with inventory available through at least 2027, and disclosed Akeso and ApolloBio development updates for INO-5412 and VGX-3100.

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Bullish Sentiment

<ul class="summary-bullets"><li>Inovio’s Voceryq secured accelerated FDA approval, with shipments expected in about 60 days and full commercial deployment in early 2027.</li><li>Papzimeos generated $53.1 million in Q2 revenue, with more than 500 patient-hub registrations reported by August.</li><li>Separate trials showed surgery-free responses of about 51% for Papzimeos and 27% for Voceryq.</li></ul>Shares of Precigen (PGEN) plunged 20% in premarket trading on Monday, but retail buyout hopes persist ahead of Wednesday’s earnings as Inovio’s newly approved rival challenges Papzimeos, Precigen’s treatment for a rare disease that causes recurring airway growths.&nbsp;<a href="https://stocktwits.com/symbol/PGEN">PGEN stock</a> fell 19% in October, ending a seven-month winning streak, but gained 12% last week for its strongest weekly performance in over a month.&nbsp;<h2 class="st-heading-2">PGEN Takeover Talk Fuels Retail Optimism</h2>On Stocktwits, PGEN sentiment climbed from ‘neutral’ a week ago to an all-time high of 94/100 in ‘extremely bullish’ territory, alongside ‘extremely high’ message volume.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/pgen_ss_c620974bba.png" alt="pgen ss.png" width="645" height="331"><figcaption>PGEN sentiment and message volume as of November 2 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Cascas007/message/667857167">said</a>, “The arrival of inovio competition doesn’t weaken the buyout thesis. it often accelerates it.” The trader suggested a sale at $15-$20 a share could become more appealing before Inovio’s commercial launch gains traction, rather than holding out for $30 or more.&nbsp;Another user&nbsp;<a href="https://stocktwits.com/JackFrost25/message/667887637">said</a>, “Surgeons, not patients or insurance companies, are going to drive treatment regimens,” arguing that physicians would favor Papzimeos as a first-line treatment.A separate user&nbsp;<a href="https://stocktwits.com/RaphaelRapoport/message/667879766">said</a>, “Coke has pepsi. PGEN has $INO -- I invested in both for a reason.” The trader hoped Precigen would report $100 million in revenue.<h2 class="st-heading-2">Inovio’s FDA Win Raises The Stakes</h2>The FDA granted accelerated approval to Inovio’s Voceryq on Friday to reduce surgeries in adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease that causes recurring airway growths.&nbsp;&nbsp;Inovio expects shipments to begin in about 60 days, with full commercial deployment in early 2027.&nbsp;The treatments differ in how surgery fits into dosing. Papzimeos requires four injections over 12 weeks, with visible growths removed before treatment and, if present, before doses three and four. Meanwhile, Voceryq also starts after surgery, but its nine-week regimen, administered using Inovio’s Cellectra device, requires no additional surgery under the dosing protocol.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/media/188264/download?attachment=&amp;utm_source=chatgpt.com">&nbsp;</a>In separate studies, 18 of 35 Papzimeos patients, or 51%, and seven of 26 Voceryq patients, or 27%, required no surgery for 12 months after treatment.&nbsp;<h2 class="st-heading-2">Papzimeos Defends Its Head Start</h2>However, Papzimeos has a commercial head start. Approved in August 2025, it generated $53.1 million in second-quarter 2026 revenue. By August, Precigen reported more than 500 patient-hub registrations and payer coverage across 315 million U.S. lives.Long-term results also support Precigen’s case. In May, 15 of 18 initial complete responders remained in response after at least three years, including five beyond four years without further RRP treatment. Papzimeos has orphan drug exclusivity through Aug.14, 2032, although Voceryq’s approval brings a different therapy into the same market.Beyond RRP, Precigen received FDA platform technology designation for AdenoVerse in September, potentially streamlining future drug development. It is studying PRGN-2009 in HPV-associated cancers and expects a portfolio update by year-end.<h2 class="st-heading-2">PGEN Q3 Preview</h2>Precigen’s revenue is expected to rise 30% from the second quarter (Q2) to $71.56 million, while earnings before interest and taxes (EBIT) is projected to increase 58% to $35.75 million. GAAP EPS is forecast at $0.08, versus $0.05 a quarter ago, according to Koyfin.On a year-over-year basis, revenue is projected at $71.56 million, up from $0.5 million. EBIT is expected to reach $35.3 million, versus a $26.13 million loss, while EPS is forecast at $0.07, versus a $0.10 loss, according to Fiscal.ai.PGEN stock has risen 66% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spacex-mirror-nvidia-revenue-boom-sequoia-partner-tesla-influencer-merger-math/cNG9YeiR92p">SpaceX Could Be The Next Nvidia – A Sequoia Partner Sees $731B In Revenue By 2028&nbsp;</a>

In this photo illustration, the Precigen's logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Precigen Bears Take Over Premarket – But Retail Bulls Still See A Buyout Coming

Precigen Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.48
Prev Close	$1.45
Open	$1.37
Dividend Yield	0.00%
50-Day Moving Average	$1.18
Beta	1.06
Avg. Volume	7.81M
PE Ratio	-1.84

52-Week High	$2.72
52-Week Low	$0.5632
Market Capitalization	$149.93M
EPS (Annual)	-$1.81
Price to Book	-4.79
Revenue Per Employee	$583.42

Feed

News

Sentiment

Earnings

Fundamentals

Info

INO Fundamentals